Literature DB >> 27757526

Clinical outcomes and antibiotic susceptibilities of Staphylococcus aureus endophthalmitis.

Jonathan I Huz1,2, Krishna Mukkamala3, Ivelisse Rodriguez Pagan2, David Ritterband4, Mahendra Shah4, Ronald C Gentile4, Michael Engelbert5,6.   

Abstract

PURPOSE: To compare the antibiotic susceptibilities and visual acuity (VA) outcomes in endophthalmitis caused by methicillin-resistant (MRSA) versus methicillin-sensitive S. aureus (MSSA).
METHODS: The records of 34 cases of S. aureus endophthalmitis at The New York Eye and Ear Infirmary from Jan 1997 to June 2011 were reviewed. Antibiotic susceptibility profiles over time and VA at presentation and at 3, 6, and ≥12 months were recorded. S. aureus isolates were grouped based on oxacillin resistance.
RESULTS: Of the 34 cases, 15 (44 %) were MRSA and 19 (56 %) MSSA. Median presenting VA was hand motions (logMAR 4.0) in both the MRSA and MSSA groups. There was no statistically significant difference in VA between the MRSA and MSSA groups at 3, 6, or ≥12 months. No MRSA isolates were resistant to vancomycin or gentamicin. While over 85 % of MRSA isolates tested for fourth-generation fluoroquinolones were resistant, just 10 % MSSA isolates tested were resistant. There was a trend suggesting an increase in the proportion of MRSA isolates compared to MSSA isolates over the course of the study period.
CONCLUSIONS: There was no statistical difference in short- or long-term VA outcomes between the MRSA and MSSA groups at any time point. Resistance to fourth-generation fluoroquinolones was present in over 85 % of MRSA isolates, but just 10 % of MSSA isolates. An increasing proportion of MRSA amongst S. aureus isolates was noted over the course of the study period.

Entities:  

Keywords:  Antibiotic sensitivity; Endophthalmitis; Retinal disorders; Staphylococcus aureus

Mesh:

Substances:

Year:  2016        PMID: 27757526     DOI: 10.1007/s00417-016-3504-x

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  20 in total

1.  ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery: Preliminary report of principal results from a European multicenter study.

Authors:  Peter Barry; David V Seal; George Gettinby; Fiona Lees; Magnus Peterson; Crawford W Revie
Journal:  J Cataract Refract Surg       Date:  2006-03       Impact factor: 3.351

Review 2.  The epidemiology, treatment, and prevention of transmission of methicillin-resistant Staphylococcus aureus.

Authors:  David P Calfee
Journal:  J Infus Nurs       Date:  2011 Nov-Dec

3.  Community-associated MRSA--resistance and virulence converge.

Authors:  Henry F Chambers
Journal:  N Engl J Med       Date:  2005-04-07       Impact factor: 91.245

Review 4.  Adhesion mechanisms of staphylococci.

Authors:  Christine Heilmann
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

5.  Antibiotic prophylaxis of postoperative endophthalmitis after cataract surgery: Results of the 2014 ASCRS member survey.

Authors:  David F Chang; Rosa Braga-Mele; Bonnie An Henderson; Nick Mamalis; Abhay Vasavada
Journal:  J Cataract Refract Surg       Date:  2015-06       Impact factor: 3.351

6.  Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients.

Authors:  Yves Gillet; Bertrand Issartel; Philippe Vanhems; Jean-Christophe Fournet; Gerard Lina; Michèle Bes; François Vandenesch; Yves Piémont; Nicole Brousse; Daniel Floret; Jerome Etienne
Journal:  Lancet       Date:  2002-03-02       Impact factor: 79.321

Review 7.  Current concepts on the virulence mechanisms of meticillin-resistant Staphylococcus aureus.

Authors:  Richard R Watkins; Michael Z David; Robert A Salata
Journal:  J Med Microbiol       Date:  2012-06-28       Impact factor: 2.472

8.  Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.

Authors:  Chirag P Shah; Sunir J Garg; James F Vander; Gary C Brown; Richard S Kaiser; Julia A Haller
Journal:  Ophthalmology       Date:  2011-06-25       Impact factor: 12.079

9.  Microbial profile and antibiotic susceptibility of culture-positive bacterial endophthalmitis.

Authors:  G B Melo; P J M Bispo; M C Z Yu; A C C Pignatari; A L Höfling-Lima
Journal:  Eye (Lond)       Date:  2011-02-18       Impact factor: 3.775

10.  Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection.

Authors:  O Artunay; E Yuzbasioglu; R Rasier; A Sengül; H Bahcecioglu
Journal:  Eye (Lond)       Date:  2009-12       Impact factor: 3.775

View more
  2 in total

1.  Disarming Pore-Forming Toxins with Biomimetic Nanosponges in Intraocular Infections.

Authors:  Phillip S Coburn; Frederick C Miller; Austin L LaGrow; Craig Land; Huzzatul Mursalin; Erin Livingston; Omar Amayem; Yijie Chen; Weiwei Gao; Liangfang Zhang; Michelle C Callegan
Journal:  mSphere       Date:  2019-05-15       Impact factor: 4.389

2.  Transcriptomics and systems biology identify non-antibiotic drugs for the treatment of ocular bacterial infection.

Authors:  Susmita Das; Sukhvinder Singh; Sarthak Satpathy; Manoj Bhasin; Ashok Kumar
Journal:  iScience       Date:  2022-08-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.